A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.
Understand this study
What is this study about?
Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.
Who could participate?
This study is for people with anxiety. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 35 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 245
- Sponsor
- Definium Therapeutics US, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, United Kingdom, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT06809595
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama
Recruitment & locations
Little Rock, United States · Los Angeles, United States · Bradenton, United States
26 more locations
- Orlando, United States
- Atlanta, United States
- Towson, United States
- Boston, United States
- Princeton, United States
- Cincinnati, United States
- North Canton, United States
- Austin, United States
- Everett, United States
- Pilsen, Czechia
- Prague, Czechia
- Douai, France
- Marseille, France
- Paris, France
- Sotteville-lès-Rouen, France
- Berlin, Germany
- Mannheim, Germany
- Tübingen, Germany
- Gdansk, Poland
- Lodz, Poland
- Glasgow, United Kingdom
- Gosforth, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Sheffield, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.
Who is behind this study?
The study sponsor is Definium Therapeutics US, Inc.
Does this study involve medication?
Yes. The study involves medication, including DT120.
Who can participate?
This study is for people with anxiety. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
